Kymera Therapeutics shares Phase 1 data supporting oral immunology pipeline
Kymera Therapeutics (NASDAQ:KYMR) reported positive findings from its Phase 1 clinical trial evaluating KT-621, a first-in-class oral small molecule STAT6 degrader, in healthy Japanese adults.
The clinical updates, shared during an oral presentation at the Japanese Dermatological Association (JDA) Annual Meeting in Kyoto, Japan, demonstrate consistent pharmacokinetics and near-complete target protein degradation, mirroring earlier data sets from Western cohorts.
The randomized, double-blind, placebo-controlled study enrolled 24 healthy Japanese participants to establish baseline safety, tolerability, and pharmacodynamic profiles within the region's demographic.
The candidate met its key evaluation criteria, achieving greater than or equal to 98% median STAT6 degradation in blood by Day 7 of administration.
The pharmacokinetic profile scaled linearly across evaluated doses, while the overall safety and tolerability metrics remained comparable to prior clinical readouts, with no severe or unexpected drug-related adverse events reported.
Targeting STAT6 allows the therapeutic candidate to block the IL-4 and IL-13 signaling pathways, which serve as central drivers in type 2 immuno-inflammatory conditions.
While existing biological therapies require subcutaneous injections, Kymera's targeted protein degradation platform is designed to achieve comparable or superior biomarker inhibition through a once-daily oral pill.
Backed by the validation of the cross-population data, the biopharmaceutical firm is maintaining its aggressive global clinical timeline.
Kymera is currently advancing parallel Phase 2b clinical trials evaluating KT-621: the BROADEN2 study in moderate-to-severe atopic dermatitis and the BREADTH study in moderate-to-severe asthma.
Management confirmed that top-line data readouts from the mid-stage dermatology trial remain on track for mid-2027, with the corresponding respiratory trial data expected to conclude by late 2027.
